Heparin and heparinoids in stroke

Neurology

Volumn 51, Issue 3 SUPPL., 1998, Pages

  Sherman, David G ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DANAPAROID; HEPARIN; NADROPARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG CHOICE; DRUG SAFETY; HEPARINIZATION; HUMAN; PRIORITY JOURNAL; STROKE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT PLANNING;

EID: 0031682148     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.3_suppl_3.s56     Document Type: Article

References (15)

1. Turpie AGG. Prophylaxis of venous thromboembolism in stroke patients. Semin Thromb Hemost 1997;23:155-157.
2. Marsh EE III, Adams HP Jr, Biller J, et al. Use of antithrombotic drugs in the treatment of acute ischemic stroke: a survey of neurologists in practice in the United States. Neurology 1989;39:1631-1634.
3. Kappelle LJ, Adams HP Jr, Torner JC, Bendixen BH. Physician attitudes towards acute stroke - a comparison of primary care physicians in Iowa and the Netherlands. Cerebrovasc Dis 1993;3:364-369.
4. Sandercock PAG, van den Belt AGM, Lindley RI, Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993;56:17-25.
5. Nurmohamed MT, ten Cate H, ten Cate JW. Low molecular weight heparin(oid)s: clinical investigations and practical recommendations. Drugs 1997;53:736-751.
6. Stein B, Fuster V. Antithrombotic therapy in acute myocardial infarction: prevention of venous, left ventricular and coronary artery thromboembolism. Am J Cardiol 1989;64:33B-40B.
7. Harenberg J, Roebruck P, Heene DL, on behalf of the Heparin Study in Internal Medicine Group. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Haemostasis 1996;26:127-139.
8. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988;208:227-240.
9. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
10. Lutomski DM, Bottorff M, Sangha K. Pharmacokinetic optimisation of the treatment of embolic disorders. Clin Pharmacokinet 1995;28:67-92.
11. Skoutakis VA. Danaparoid in the prevention of thromboembolic complications. Ann Pharmacother 1997;31:876-887.
12. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
13. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-1593.
14. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
15. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke. A randomized controlled trial. JAMA 1998;279:1265-1272.